Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon plc has repurchased 2,749,486 ordinary shares for cancellation under the share buyback programme it launched on 12 March 2026, executing trades across the London Stock Exchange, Cboe venues and Aquis at volume-weighted average prices around 373–375 pence. Following settlement, the company’s registered share capital stands at 8,949,604,162 ordinary shares, of which 43,651,673 are held in treasury, leaving 8,905,952,489 shares with voting rights, a new baseline for investors assessing disclosure thresholds under UK transparency rules.
The adjustment to Haleon’s share count through buybacks and treasury holdings slightly concentrates remaining shareholders’ economic and voting interests, while signalling ongoing capital management efforts by the consumer health group. The updated voting share figure also provides clarity to institutional and other investors on when they must report changes in their holdings under the Financial Conduct Authority’s disclosure regime.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon plc, listed in London and New York, is a consumer health company focused on improving everyday health through over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin care, anchored by global brands such as Sensodyne, Panadol, Advil, Voltaren and Centrum that are used by over a billion consumers and recommended by health professionals worldwide.
Average Trading Volume: 18,411,593
Technical Sentiment Signal: Strong Buy
Current Market Cap: £33.39B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.